Stockscreener 앱 받기
2.00
2.56%
0.05
시간 외 거래:
1.95
-0.05
-2.50%
Medicinova Inc 주식(MNOV)의 최신 뉴스
MediciNova reports progress in ALS and Long COVID trials - Investing.com
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders - GlobeNewswire
MediciNova Partners with NIH for ALS Trial, Reports $42.3M Cash Position | MNOV Stock News - StockTitan
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com - MarketBeat
MediciNova Receives Notice of Allowance from United States - GlobeNewswire
MediciNova Secures Key Patent for Diabetes Treatment MN-001 Through 2042 | MNOV Stock News - StockTitan
MediciNova stock hits 52-week high at $2.17 amid growth - Investing.com India
MediciNova: Q3 Earnings Snapshot - New Haven Register
3 US Penny Stocks With Market Caps Over $40M To Consider - Simply Wall St
MediciNova stock hits 52-week high at $2.17 amid growth By Investing.com - Investing.com UK
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis - The Manila Times
MediciNova Secures Major Settlement from Sanofi-Novartis Litigation, Boosts Clinical Pipeline | MNOV Stock News - StockTitan
Idiopathic Pulmonary Fibrosis Management Market Share and Size Report 2024-2031 - InsightAce Analytic
MediciNova (NASDAQ:MNOV shareholders incur further losses as stock declines 11% this week, taking five-year losses to 80% - Simply Wall St
MediciNova (NASDAQ:MNOV) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - MarketBeat
TSX Buyback Index (TXBB) QuotePress Release - The Globe and Mail
Idiopathic Pulmonary Fibrosis Market Is Booming Worldwide - openPR
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - Defense World
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average – Should You Sell? - Defense World
MediciNova (NASDAQ:MNOV) Stock Price Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Clean Harbors (CLH-N) QuotePress Release - The Globe and Mail
MediciNova Announces Update of Phase 2/3 Clinical Trial of - GlobeNewswire
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) - StockTitan
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - MarketBeat
MediciNova (NASDAQ:MNOV) Research Coverage Started at StockNews.com - Defense World
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
MediciNova, Inc. (NASDAQ:MNOV) Shares Sold by Dimensional Fund Advisors LP - Defense World
Type 1 Diabetes Market Report 2034: Epidemiology Data, Pipeline - openPR
MediciNova (NASDAQ:MNOV) shareholders have endured a 73% loss from investing in the stock five years ago - Yahoo Finance
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
MNOV: MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS - Smartkarma
MNOVMedicinova, Inc. Latest Stock News & Market Updates - StockTitan
Short Interest in MediciNova, Inc. (NASDAQ:MNOV) Rises By 19.3% - MarketBeat
MediciNova to Support NIH-Funded Expanded Access Clinical - GlobeNewswire
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) - StockTitan
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average of $1.42 - MarketBeat
Amyotrophic Lateral Sclerosis Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024 - The Globe and Mail
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Stockhouse Publishing
Insigneo Advisory Services LLC Has $6.10 Million Stock Position in Mastercard Incorporated (NYSE:MA) - Defense World
Intech Investment Management LLC Takes Position in MSA Safety Incorporated (NYSE:MSA) - MarketBeat
Minerals Technologies (NYSE:MTX) Upgraded at StockNews.com - MarketBeat
Monroe Capital (NASDAQ:MRCC) Stock Crosses Above 200 Day Moving Average of $7.49 - MarketBeat
MARXU stock soars to all-time high of $12.15 amid market optimism - Investing.com Australia
Marcus (NYSE:MCS) Upgraded by StockNews.com to Hold - Defense World
Mistras Group senior EVP sells over $349k in company stock - Investing.com
Contact Levi & Korsinsky by September 24, 2024 Deadline to Join Class Action Against MacroGenics, Inc.(MGNX) - Stockhouse Publishing
Summit Trail Advisors LLC Buys 403 Shares of Moderna, Inc. (NASDAQ:MRNA) - Defense World
MacroGenics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationMGNX - Longview News-Journal
MasterBrand (NYSE:MBC) Hits New 52-Week High at $19.10 - MarketBeat
ProShare Advisors LLC Sells 43,073 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Mutual of America Capital Management LLC Cuts Position in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mutual of America Capital Management LLC Decreases Stake in MSA Safety Incorporated (NYSE:MSA) - Defense World
2024-09-23 | Shareholders that lost money on MacroGenics, Inc.(MGNX) Urged to Join Class ActionContact The Gross Law Firm to Learn More | NDAQ:MGNX | Press Release - Stockhouse Publishing
0.93%
3.55%
자본화:
|
볼륨(24시간):